302 related articles for article (PubMed ID: 31240525)
1. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
2. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
3. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
[TBL] [Abstract][Full Text] [Related]
4. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
5. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.
Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
Eur Spine J; 2014 Nov; 23(11):2416-22. PubMed ID: 24929808
[TBL] [Abstract][Full Text] [Related]
7. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors.
Tamura R; Sato M; Morimoto Y; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Murase M; Yoshida K; Toda M
Exp Mol Pathol; 2020 Jun; 114():104408. PubMed ID: 32088190
[TBL] [Abstract][Full Text] [Related]
10. Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases.
Jambhekar NA; Rekhi B; Thorat K; Dikshit R; Agrawal M; Puri A
Arch Pathol Lab Med; 2010 Aug; 134(8):1181-7. PubMed ID: 20670140
[TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
[TBL] [Abstract][Full Text] [Related]
12. New Prospects for Molecular Targets for Chordomas.
Ozair MZ; Shah PP; Mathios D; Lim M; Moss NS
Neurosurg Clin N Am; 2020 Apr; 31(2):289-300. PubMed ID: 32147018
[TBL] [Abstract][Full Text] [Related]
13. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J
J Neurosurg; 2019 Jan; 132(1):140-149. PubMed ID: 30641849
[TBL] [Abstract][Full Text] [Related]
14. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.
Talagas M; Uguen A; Garlantezec R; Fournier G; Doucet L; Gobin E; Marcorelles P; Volant A; DE Braekeleer M
Anticancer Res; 2013 May; 33(5):2065-75. PubMed ID: 23645757
[TBL] [Abstract][Full Text] [Related]
15. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
16. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
[TBL] [Abstract][Full Text] [Related]
18. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.
Färkkilä A; Anttonen M; Pociuviene J; Leminen A; Butzow R; Heikinheimo M; Unkila-Kallio L
Eur J Endocrinol; 2011 Jan; 164(1):115-22. PubMed ID: 21041381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
